Phospho-IRAK1 (T100) Antibody

What is Phospho-IRAK1 (T100) Antibody and what is its specificity?

Phospho-IRAK1 (T100) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of IRAK1 (Interleukin-1 receptor-associated kinase 1) only when phosphorylated at threonine 100. This antibody does not cross-react with unphosphorylated IRAK1 or other phosphorylated proteins. The specificity is achieved through the immunization strategy using a synthetic peptide derived from human IRAK1 around the phosphorylation site of Thr100 (amino acids 66-115) .

The antibody undergoes rigorous purification through affinity chromatography using the immunizing phospho-peptide, ensuring high specificity for the phosphorylated epitope . Validation typically involves demonstrating reduced or absent signal after treatment with phosphatase or with blocking peptides specific to the phosphorylated region.

What are the recommended applications and species reactivity for this antibody?

This antibody has been validated for multiple research applications with these recommended dilutions:

The antibody has confirmed reactivity with:

• Human

• Mouse

• Rat

Some manufacturers predict cross-reactivity with additional species including pig, zebrafish, bovine, horse, sheep, rabbit, and dog based on sequence homology, though these predictions require experimental validation .

How should I optimize Western Blot protocols for detecting phosphorylated IRAK1?

Optimizing Western blot protocols for phosphorylated proteins requires special considerations:

• Sample preparation: Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in your lysis buffer to prevent dephosphorylation during extraction.

• Blocking buffer selection: Use 5% BSA in TBST rather than milk, as milk contains casein phosphoproteins that may increase background.

• Dilution optimization:

  • Start with manufacturer's recommended range (1:500-1:1000)

  • Perform a dilution series (e.g., 1:250, 1:500, 1:1000, 1:2000)

  • Assess signal-to-noise ratio at each dilution

• Positive control inclusion: Include lysates from cells stimulated with LPS or IL-1, which are known to induce IRAK1 phosphorylation .

• Membrane stripping considerations: If you plan to strip and reprobe the membrane, use gentle stripping methods as harsh conditions may remove phospho-epitopes.

• Detection system selection: Enhanced chemiluminescence (ECL) substrates with longer signal duration are recommended for initial optimization .

What controls should be included when using Phospho-IRAK1 (T100) Antibody?

Including appropriate controls is critical for interpreting phospho-specific antibody results:

Essential controls:

• Positive control: Lysates from cells treated with LPS (100 ng/ml) or IL-1β (10 ng/ml) for 5-15 minutes, which induces IRAK1 phosphorylation .

• Negative control:

  • Unstimulated cells

  • Samples treated with phosphatase

  • Cells treated with IRAK1/4 inhibitor (500 nM, 3-hour pretreatment)

• Antibody controls:

  • Secondary antibody only control

  • Isotype control (general rabbit IgG at equivalent concentration)

  • Blocking peptide competition (pre-incubate antibody with immunizing phosphopeptide)

• Loading control: Anti-β-actin or total IRAK1 antibody to normalize protein loading

• Molecular weight verification: Confirm the detected band appears at the expected molecular weight of 76-77 kDa .

What are the optimal cell stimulation conditions to detect IRAK1 T100 phosphorylation?

IRAK1 T100 phosphorylation can be induced through several stimulation conditions:

For optimal results:

• Stimulation timing: Perform a time-course experiment (5, 15, 30, 60 minutes) to identify peak phosphorylation.

• Cell density: Use cells at 80-90% confluence for adherent cells or 1-2 × 10^6 cells/ml for suspension cells.

• Serum starvation: Starve cells in serum-free medium for 4-6 hours before stimulation to reduce background phosphorylation.

• Rapid processing: Quickly lyse cells after stimulation to preserve phosphorylation status .

How can I validate the specificity of Phospho-IRAK1 (T100) Antibody in my experimental system?

Validating phospho-specific antibody specificity requires multiple complementary approaches:

• Phosphatase treatment:

  • Split your sample into two aliquots

  • Treat one with lambda phosphatase (400 units, 30 minutes at 30°C)

  • Compare with untreated sample - signal should decrease or disappear in treated sample

• Genetic approaches:

  • Use CRISPR/Cas9 to create IRAK1 knockout cells

  • Perform site-directed mutagenesis to create T100A mutant

  • Both should show absence of specific signal

• Pharmacological inhibition:

  • Pretreat cells with IRAK1/4 inhibitor (500 nM, 3 hours)

  • Compare with untreated stimulated cells

• Peptide competition:

  • Pre-incubate antibody with excess phospho-peptide (10-100 μg/ml)

  • Compare with antibody alone - specific signal should be blocked

• Correlation with known stimuli:

  • Compare phosphorylation patterns with published literature

  • Use time course and dose response to established stimuli .

What are the best approaches for quantifying IRAK1 phosphorylation levels?

Accurate quantification of IRAK1 phosphorylation requires proper normalization and analysis:

• Western blot densitometry:

  • Capture images within linear dynamic range of detection

  • Normalize phospho-IRAK1 signal to total IRAK1 or housekeeping protein

  • Express as fold change relative to control condition

  • Use software like ImageJ or specialized densitometry tools

• Cell-based ELISA approach:

  • Use cell-based ELISA kits designed for phospho-IRAK1 detection

  • Follow the assay principle that captures phospho-IRAK1 with specific antibodies

  • Normalize using included GAPDH control antibody

  • Calculate ratio of phosphorylated to total IRAK1

• Flow cytometry quantification:

  • Fix and permeabilize cells after stimulation

  • Stain with fluorophore-conjugated phospho-IRAK1 antibody

  • Include appropriate isotype controls

  • Analyze mean fluorescence intensity (MFI)

  • Gate on specific cell populations if using mixed cell types

• Phospho-proteomic MS approach:

  • For comprehensive phosphorylation analysis

  • Provides absolute quantification of multiple phosphorylation sites

  • Requires specialized equipment and expertise

How can I troubleshoot weak or non-specific signals when using this antibody?

When encountering issues with phospho-IRAK1 antibody performance, systematic troubleshooting is essential:

For weak signals:

• Increase protein loading (30-50 μg/lane instead of standard 20 μg)

• Reduce antibody dilution (try 1:250 if 1:500 gives weak signal)

• Extend primary antibody incubation (overnight at 4°C)

• Use enhanced detection systems (high-sensitivity ECL substrates)

• Optimize stimulation conditions (time course experiment)

• Ensure phosphorylation is preserved (use fresh phosphatase inhibitors)

For non-specific signals:

• Increase blocking time and concentration (5% BSA, 2 hours at RT)

• Increase washing duration and frequency (6 × 10 minutes instead of 3 × 5 minutes)

• Optimize antibody dilution (try more dilute, e.g., 1:1000 instead of 1:500)

• Reduce exposure time during detection

• Validate bands with positive controls and molecular weight markers

• Use alternative buffers (try TBS-T instead of PBS-T)

• Consider using monoclonal antibody alternatives if available .

What is the relationship between IRAK1 T100 phosphorylation and disease models?

IRAK1 phosphorylation at T100 has been implicated in several disease contexts:

• Inflammatory disorders:

  • Increased IRAK1 T100 phosphorylation observed in chronic inflammatory conditions

  • Target for anti-inflammatory therapeutic development

  • Biomarker for TLR/IL-1R pathway activation

• Cancer biology:

  • Constitutive IRAK1 activation (including T100 phosphorylation) in certain cancers

  • Associated with tumor progression and treatment resistance

  • Potential therapeutic target in cancer treatment

• Innate immunity:

  • Critical role in dendritic cell IL-12 response

  • IRAK1/IRF5 axis importance in immune response

  • Different requirements between cell types (DCs vs. monocyte-derived DCs)

• Infectious disease:

  • Modulation by pathogens to evade immune response

  • Essential for host response to bacterial and viral challenges

  • Differential regulation in T. gondii exposure

• Therapeutic targeting:

  • IRAK1/4 inhibitors under development for inflammatory diseases

  • Monitoring T100 phosphorylation as pharmacodynamic marker

  • Structure-based virtual screening approaches for inhibitor development

How can I use the Phospho-IRAK1 (T100) antibody in combination with other techniques?

Integrating Phospho-IRAK1 (T100) antibody detection with complementary techniques enhances research insights:

• Co-immunoprecipitation studies:

  • Use anti-IRAK1 antibody for IP followed by phospho-specific detection

  • Detect interaction partners in phosphorylation-dependent manner

  • Follow established protocols with high stringency lysis buffer (50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Nonidet P-40)

• Immunofluorescence microscopy:

  • Track subcellular localization changes upon phosphorylation

  • Co-localization with interacting proteins or organelles

  • Use 4% paraformaldehyde fixation and Triton X-100 permeabilization

• Phosphorylation-dependent functional assays:

  • Correlate T100 phosphorylation with downstream functional outcomes

  • Measure NF-κB activation using reporter assays

  • Assess cytokine production (e.g., IL-6, TNF-α)

• Kinase activity assays:

  • Compare phosphorylation status with IRAK1 kinase activity

  • Mobility shift assays as used in inhibitor screening

  • In vitro kinase assays with substrates like Pellino proteins

• Multi-phosphorylation site analysis:

  • Parallel detection of T100 with other sites (T387, S376)

  • Sequential blotting after careful stripping

  • Correlation of phosphorylation timing across multiple sites

What are the key methodological considerations for Cell-Based ELISA using Phospho-IRAK1 (T100) Antibody?

The Cell-Based ELISA approach offers unique advantages for quantifying IRAK1 phosphorylation in intact cells:

Principle of the assay:
The IRAK1 (phospho Thr100) Cell-Based ELISA uses an indirect ELISA format where phospho-IRAK1 is captured by specific antibodies. Detection occurs through dye-conjugated secondary antibodies binding to the primary antibody, enabling fluorometric detection .

Key methodological steps:

• Cell preparation:

  • Seed cells in 96-well plates (minimum 5000 cells/well)

  • Grow to 70-80% confluence

  • Stimulate with appropriate ligands

• Fixation and permeabilization:

  • Fix with 4% paraformaldehyde (10 minutes, RT)

  • Permeabilize with 0.1% Triton X-100 (5 minutes, RT)

  • Block with optimization buffer (1 hour, RT)

• Antibody incubation:

  • Primary: Phospho-IRAK1 (T100) and control antibodies

  • Secondary: Dye-conjugated detection antibodies

  • Follow manufacturer's dilution recommendations

• Normalization approach:

  • GAPDH detection serves as internal control

  • Total IRAK1 detection allows phospho/total ratio calculation

  • Calculate relative fluorescence units (RFU) values

• Data analysis:

  • Normalize phospho-IRAK1 signal to GAPDH

  • Calculate phospho/total IRAK1 ratio

  • Compare across experimental conditions

This approach allows high-throughput analysis of IRAK1 phosphorylation across multiple conditions while maintaining cells in their physiological context.

How can I optimize immunohistochemistry protocols for Phospho-IRAK1 (T100) detection in tissue sections?

Detecting phosphorylated proteins in tissue sections presents unique challenges requiring specific optimization:

• Tissue preparation considerations:

  • Use freshly collected tissues when possible

  • Fix immediately after collection (phosphorylation is labile)

  • Prefer zinc-based fixatives over formalin when possible

  • Limit fixation time to prevent epitope masking

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0)

  • Try alternative buffers (Tris-EDTA, pH 9.0) if signal is weak

  • Optimize retrieval time (10-20 minutes)

• Blocking and detection:

  • Use 5% normal serum from secondary antibody species + 1% BSA

  • Apply antibody at 1:100-1:300 dilution (start with higher concentration)

  • Incubate overnight at 4°C for optimal sensitivity

  • Use biotin-free detection systems to reduce background

• Controls and validation:

  • Include positive control tissues (LPS-stimulated spleen sections)

  • Adjacent sections with phosphatase treatment

  • Peptide competition controls

  • Isotype controls at matching concentration

• Signal enhancement:

  • Tyramide signal amplification for weak signals

  • Polymer-based detection systems

  • Extended chromogen development with monitoring

When analyzing results, remember that tissue fixation can affect phospho-epitope preservation, so relative rather than absolute quantification is recommended.

What artificial intelligence and computational approaches can enhance Phospho-IRAK1 research?

Recent advances in computational biology offer powerful tools for phosphorylation research:

• Virtual screening for IRAK1 inhibitors:

  • Support Vector Machine (SVM) models integrate multiple parameters

  • Combine docking scores, pharmacophore mapping, and molecular descriptors

  • Significantly improve prediction accuracy (>50% exclusion of inactive compounds)

  • Structure-based virtual screening using PDB ID: 6BFN (human wild-type IRAK1)

• Phosphorylation site prediction:

  • Computational algorithms predict phosphorylation probability

  • Context-dependent sequence analysis

  • Structural modeling of kinase-substrate interactions

• Network analysis of phosphorylation cascades:

  • Pathway integration of IRAK1 phosphorylation events

  • Temporal modeling of phosphorylation dynamics

  • Identification of feedback mechanisms

• Image analysis for quantification:

  • Machine learning algorithms for automated western blot quantification

  • Deep learning approaches for IHC image analysis

  • Reduction of subjective interpretation bias

• Systems biology approaches:

  • Integration of phosphoproteomic data with transcriptomics

  • Prediction of pathway activation from multiple phosphorylation events

  • Development of mathematical models of TLR/IL-1R signaling networks